Company Profile – Hylabs Seegene
Hylabs-Seegene
Hylabs-Seegene is Hylabs’ groundbreaking subsidiary company established in strategic partnership with Seegene Inc., South Korea’s molecular diagnostics leader. As the first company globally to join Seegene’s OneSystem™ Business initiative, we are pioneering a revolutionary approach to create a world free from diseases through advanced diagnostic technology. Hylabs-Seegene serves as Seegene’s strategic extension in Israel, combining cutting-edge syndromic PCR technology with local expertise. We represent “NewCo 1” – the prototype for Seegene’s ambitious plan to establish partnerships with leading companies in 100 countries by 2028.
Three Essential Enabling Technologies:
- Superior Syndromic qPCR Technology – Testing up to 15 pathogens simultaneously in a single tube with quantitative results
- Technology-Sharing Tools (SGDDS) – Automated development systems enabling global scientists to participate in creating diagnostic solutions
- Modular Automated Instruments (AIOS) – Universal systems compatible with all syndromic qPCR assays across all fields
What We're Here to Solve
Pandemic Preparedness & Response
- Local development capabilities for rapid response to health emergencies
- Elimination of dependency on foreign diagnostic products during crises
- Establishment of resilient healthcare infrastructure
Diagnostic Revolution
- Transformation from single-target testing to comprehensive syndromic diagnosis
- Making advanced molecular diagnostics accessible to laboratories of all sizes
- Enabling same-day results instead of delayed testing
Global Health Equity
- Localized production of customized diagnostic solutions
- Affordable access to world-class molecular diagnostic technology
- Regional customization for specific healthcare needs
Our Role as Seegene's Regional Extension
Technology & Expertise Hub
- Access to Seegene’s complete OneSystem™ package of technologies and expertise
- Local adaptation and development of syndromic PCR assays
- Training and knowledge transfer center for the regional scientific community
Manufacturing & Innovation Center
- Local production capabilities reducing supply chain vulnerabilities
- On-site development and regulatory approval for hundreds of products annually
- Customized product development for regional healthcare demands
Our Technology Foundation
Syndromic Quantitative PCR Technology Our technology is based on advanced quantitative PCR that enables simultaneous detection of up to 15 pathogens in a single tube, unlike conventional PCR that tests only 3-4 targets.
Open Innovation Program Through partnership with Springer Nature, we connect scientists worldwide to develop diagnostic solutions across all fields – from infectious diseases to cancer detection.
All-in-One System (AIOS) Automated instruments providing complete sample-to-result workflow for laboratories with minimal PCR experience.
Our Commitment to Advancing Global Health
Hylabs-Seegene embodies both companies’ commitment to advancing global health through accessible, accurate, and rapid diagnostics. Hylabs-Seegene is ready to transform molecular diagnostics in Israel and beyond, contributing to a future where advanced diagnostic capabilities are universally accessible, helping create A World Free from All Diseases.
Hylabs-Seegene: Pioneering the future of molecular diagnostics through global collaboration and technological excellence.